Unity Biotechnology (LTS:0YC0) Interest Expense: $0.00 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0YC0 Unity Biotechnology Inc LTS:0YC0
25 GF Score
Price $0.06
View Full Analysis

What is Unity Biotechnology Interest Expense?

Unity Biotechnology LTS:0YC0 25 Interest Expense is $0.00 Mil as of Mar. 2025. GuruFocus rates LTS:0YC0 with a GF Score™ of 25/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Unity Biotechnology's interest expense for the three months ended in Mar. 2025 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Unity Biotechnology's Operating Income for the three months ended in Mar. 2025 was $ -6.89 Mil. Unity Biotechnology's Interest Expense for the three months ended in Mar. 2025 was $ 0.00 Mil. GuruFocus does not calculate Unity Biotechnology's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Unity Biotechnology  (LTS:0YC0) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Unity Biotechnology's Interest Expense for the three months ended in Mar. 2025 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was $-6.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was $18.68 Mil.

Unity Biotechnology's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

GuruFocus does not calculate Unity Biotechnology's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Unity Biotechnology Interest Expense Historical Data

* Premium members only.

The historical data trend for Unity Biotechnology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Unity Biotechnology Interest Expense Chart

Unity Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Interest Expense
Get a 7-Day Free Trial Premium Member Only -1.29 -3.18 -3.56 -2.45 0.00

Unity Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0YC0
25GF Score
Unity Biotechnology Inc LTS:0YC0
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Unity Biotechnology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
Unity Biotechnology (LTS:0YC0) has a Interest Expense of $0.00 Mil as of Mar. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Unity Biotechnology and its competitors.
Is Unity Biotechnology's Interest Expense too high?
Unity Biotechnology's current Interest Expense is $0.00 Mil. Overall, Unity Biotechnology has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Unity Biotechnology's Interest Expense compare to ADTX and HEPA?
Unity Biotechnology's Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Unity Biotechnology and its competitors. Unity Biotechnology's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unity Biotechnology stock overvalued right now?
Unity Biotechnology (LTS:0YC0) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Unity Biotechnology's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Unity Biotechnology (LTS:0YC0), the current Interest Expense is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Unity Biotechnology Business Description

Address 285 East Grand Avenue, South San Francisco, CA, USA, 94080
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
25GF Score

Get the complete analysis for LTS:0YC0

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price